CDKN2A and cancer: Furthermore, study of 356 patients from Dana-Farber/Brigham and Women’s Cancer Center [24] and our results derived from the TCGA PAAD datasets showed that the KRAS, TP53 mutation and CDKN2A deletion were synergistically determined the clinical overall survival of patients with pancreatic cancer.